In today’s recent session, 0.94 million shares of the Arcutis Biotherapeutics Inc (NASDAQ:ARQT) have been traded, and its beta is 1.86. Most recently the company’s share price was $15.28, and it changed around -$0.13 or -0.85% from the last close, which brings the market valuation of the company to $1.82B. ARQT at last check was trading at a discount to its 52-week high of $17.75, offering almost -16.16% off that amount. The share price’s 52-week low was $6.99, which indicates that the recent value has risen by an impressive 54.25% since then.
Arcutis Biotherapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended ARQT as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Arcutis Biotherapeutics Inc is expected to report earnings per share of -0.21 for the current quarter.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Instantly ARQT has been showing red trend so far today with a performance of -0.85% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 15.67 on recent trading dayincreased the stock’s daily price by 2.49%. The company’s shares are currently up 9.68% year-to-date, but still up 3.59% over the last five days. On the other hand, Arcutis Biotherapeutics Inc (NASDAQ:ARQT) is 3.73% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $19, which translates to bulls needing to increase their stock price by 19.58% from its current value. Analyst projections state that ARQT is forecast to be at a low of $19 and a high of $19.
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
The year-over-year growth rate is expected to be 55.25%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 62.48M in revenue for the current quarter. 5 analysts expect Arcutis Biotherapeutics Inc to make 71.46M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 49.57M and 30.86M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 26.05%. Forecasts for the next quarter put sales growth at 131.58%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -0.98%.
ARQT Dividends
Arcutis Biotherapeutics Inc’s next quarterly earnings report is expected to be released in June.
SUVRETTA CAPITAL MANAGEMENT, LLC, with 8.1021% or 10.0 million shares worth $93.04 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Prudential Jennison Small Co Fd., Inc.-PGIM JENNISON SMALL COMPANY Fd. were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.23 shares worth $49.45 million, making up 2.71% of all outstanding shares. On the other hand, Prudential Jennison Small Co Fd., Inc.-PGIM JENNISON SMALL COMPANY Fd. held roughly 3.09 shares worth around $47.27 million, which represents about 2.59% of the total shares outstanding.
